SLV-334

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameSLV-334
Drug Alias NameSLV-334
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEndothelin-converting enzyme 1 inhibitorsEndothelin-converting enzyme 2 inhibitorsNeprilysin inhibitors
TargetsEndothelin-converting enzyme 2NeprilysinEndothelin-converting enzyme 1
Therapy Area/IndicationsBrain Injuries, Traumatic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyIsrael +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott Products
Active IndicationsN/A
Inactive IndicationsBrain Injuries, Traumatic

Other Information

ATC CodeN/A
Related LinksN/A